Bank of Montreal’s Cardiol Therapeutics CRDL Stock Holding History

Bank of Montreal’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-279,300	Closed	-$415K	–	4144
2022 Q1	$415K	Buy	+279,300	New	+$461K	﹤0.01%	2971

Other funds holding CRDL

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Bank of Montreal's CRDL Position: Q3 2025 in Review

Bank of Montreal sold out of Cardiol Therapeutics (CRDL) in Q3 2025, closing a stake of 50,000 shares — an estimated $68K sold.

Bank of Montreal first reported a position in CRDL in Q1 2022 and held it in 13 quarters. The position peaked at $110K in Q2 2023. 48 funds tracked by Wall St. Rank hold CRDL as of Q3 2025.

Bank of Montreal reported no remaining Cardiol Therapeutics position as of Q3 2025 after selling out during the quarter.
Bank of Montreal sold 50,000 Cardiol Therapeutics shares in Q3 2025, an estimated $68K.
Bank of Montreal first reported a position in Cardiol Therapeutics in Q1 2022 and held it in 13 quarters.
Bank of Montreal's Cardiol Therapeutics position peaked at $110K in Q2 2023.
48 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2025.

Based on Bank of Montreal's 13F filing for Q3 2025, filed 13 Nov 2025.